Daiichi Sankyo Company and DarwinHealth, a New York-headquartered technology-focused cancer medicine company, have formed a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s proprietary cancer target database in order to identify potential new targets for cancer drug development.  

DarwinHealth’s proprietary database and technology were created to identify critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations and include information on master regulators of specific tumor subtypes as well as direct upstream modulators (both necessary for cancer cell maintenance) across more than 35 tumor and 90 tumor subtypes. 

DarwinHealth will receive an upfront payment and has the potential to receive development and commercialization milestone payments should specified events occur relating to DarwinHealth’s cancer targets. Daiichi Sankyo will receive exclusive access to DarwinHealth’s cancer target database for a predetermined amount of time with an option to extend. Financial terms of the agreement were not disclosed.

Source: Daiichi Sankyo